R 1530 – 25 mg

Brand:
Cayman
CAS:
882531-87-5
Storage:
-20
UN-No:
Non-Hazardous - /

R 1530 is a multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively).{33271} It also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively.{33271} In cells, R 1530 delays mitosis, induces polyploidy, and blocks angiogenesis, ultimately promoting apoptosis or senescence.{33271,33272} R 1530 strongly inhibits human tumor cell proliferation and reduces the growth of tumors in cancer xenograft models.{33270}  

 

SKU: - Category:

Description

A multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively); also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively


Formal name: 5-(2-chlorophenyl)-7-fluoro-1,2-dihydro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine

Synonyms: 

Molecular weight: 356.8

CAS: 882531-87-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cell Biology|Cell Cycle||Research Area|Cell Biology|Cell Death|Apoptosis